The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
Check out some of NeurologyLive®'s featured content in the carousel below.
New Treatments in Migraine: An In-Depth Review
June 16th 2022Although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.
Tremeau Pharmaceuticals Gets IND Go-Ahead for Rofecoxib Reformulation, Dubbed TRM-201
June 15th 2022The oral tablet formulation of rofecoxib has been shown to reach maximum plasma concentrations at 2 hours post dose compared with 3 for the historical formulation, which the company believes can improve the time to onset of action.
The Effect of Mindfulness Practices on Migraine: Paige Estave, PhD
June 15th 2022The MD-PhD student at Wake Forest School of Medicine shared her perspective on the findings of a study suggesting that mindfulness practices can alter pain perception and migraine attack awareness, among other results. [WATCH TIME: 4 minutes]
Children, Adolescents With Migraine Show High Risk for Anxiety and Depression Symptoms
June 14th 2022A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.
The Endocannabinoid System and its Relationship to Migraine: Tally Largent-Milnes, PhD
June 13th 2022The assistant professor of pharmacology at the University of Arizona College of Medicine Tucson shared her insight into the endocannabinoid system and its therapeutic potential in treating migraine. [WATCH TIME: 5 minutes]
Neuronal Complexity in a Model of Migraine: Amynah Pradhan, PhD
June 12th 2022The associate professor of psychiatry at the University of Illinois at Chicago shared the findings of her and colleagues’ work that suggest that distinct cytoarchitectural changes occur in the brain that may underlie migraine chronification. [WATCH TIME: 4 minutes]
Anxiety and Depression in Children and Adolescents With Migraine: Serena L. Orr, MD, MSc
June 12th 2022The pediatric neurologist and headache specialist at the University of Calgary discussed the work she presented at AHS 2022 on the incidence of anxiety and depressive disorders in the pediatric migraine population. [WATCH TIME: 6 minutes]
Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence
June 11th 2022Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.
Rimegepant Is Well-Tolerated and Safe for Migraine Over 1 Year With Every-Other-Day Dosing
June 10th 2022Patients in the open-label extension also showed limited need for acute treatment with rimegepant (Nurtec ODT; Biohaven Pharmaceuticals), as more than 80% of patients took 16 or fewer total tablets over the 28-day period.
The Need for Effective Treatments for Status Migrainosus: Matthew Robbins, MD
June 10th 2022The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the hot topics at the American Headache Society Annual Scientific Meeting, including a presentation on the prevalence of status migrainosus. [WATCH TIME: 4 minutes]
Assessing Psychedelics for Therapeutic Potential in Cluster Headache: Bryan Roth, MD, PhD
June 9th 2022The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine shared his insight into his keynote address at the American Headache Society Annual Scientific Meeting. [WATCH TIME: 8 minutes]